Kaskela Law LLC is investigating potential breach of fiduciary duty claims concerning Semtech Corporation (NASDAQ: SMTC) (“Semtech”) on behalf of the company’s long-term shareholders.
Semtech designs, develops, manufactures, and markets analog and mixed-signal semiconductor and advanced algorithms. Semtech’s portfolio includes CopperEdge products, which can be used in active copper cables.
Recently a federal securities fraud complaint was filed against Semtech on behalf of certain investors who purchased shares of the company’s stock between October 10, 2024 and February 7, 2025 (the “Relevant Period”). According to the complaint, during the Relevant Period the defendants made a series of materially false and/or misleading statements to investors, and failed to disclose that: (i) Semtech’s CopperEdge products did not meet the needs of its server rack customer or end users; (ii) as a result, the CopperEdge products required certain rack architecture changes; (iii) consequently, Semtech’s sales of CopperEdge products would not ramp-up during fiscal 2026; and (iv) as such, sales of CopperEdge products would be lower-than-expected.
As further detailed in the complaint, on February 7, 2025, Semtech revealed that “net sales from its CopperEdge products used in active copper cables are expected to be lower than the Company’s previously disclosed floor case estimate of $50 million due to rack architecture changes, with no expected ramp-up over the course of fiscal year 2026.” On this news, shares of Semtech’s common stock fell approximately 31% in value on unusually heavy trading volume.
In light of the foregoing, Kaskela Law is investigating whether Semtech’s officers and directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.
Current Semtech shareholders who have continuously held SMTC shares since at least October 10, 2024 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at [email protected], or by completing the form on this page.